Purpose: Preclinical data demonstrating androgen receptor (AR)–positive (AR+) triple-
negative breast cancer (TNBC) cells are sensitive to AR antagonists, and PI3K inhibition …

Triple-negative breast cancer (TNBC) is an aggressive subtype associated with frequent
recurrence and metastasis. Unlike hormone receptor-positive subtypes, treatment of TNBC …

Triple-negative breast cancer represents approximately 15%-20% of all newly diagnosed
breast cancers, but it accounts for a disproportionate number of breast cancer-related deaths …

Among different types of breast cancers (BC), triple-negative BC (TNBC) amounts to 15% to
20% of breast malignancies. Three principal characteristics of TNBC cells are (i) extreme …

Luminal androgen receptor (LAR) breast cancer accounts for 10% of all triple-negative
breast cancers (TNBC). Anti-androgen therapy for this subtype is in development, but yields …

1003 Background: The AR may be a therapeutic target for pts with androgen-driven TNBC.
ENZA, a potent AR inhibitor, is approved in men with metastatic castration-resistant prostate …

Triple-negative breast cancer (TNBC) is an aggressive disease with outcomes inferior to
those of other breast cancer subtypes. No targeted therapies are currently approved for …

Introduction Triple negative breast cancer (TNBC) is a heterogeneous collection of
biologically diverse cancers, which contributes to variable clinical outcomes. Previously, we …

Purpose Studies suggest that a subset of patients with triple-negative breast cancer (TNBC)
have tumors that express the androgen receptor (AR) and may benefit from an AR inhibitor …

Background Triple-negative breast cancers (TNBCs) are clinically aggressive subtypes of
breast cancer. TNBC is difficult to treat with targeted agents due to the lack of commonly …